Sühendan Ekmekçioglu

7.6k total citations
47 papers, 2.4k citations indexed

About

Sühendan Ekmekçioglu is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Sühendan Ekmekçioglu has authored 47 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 23 papers in Immunology and 20 papers in Molecular Biology. Recurrent topics in Sühendan Ekmekçioglu's work include CAR-T cell therapy research (10 papers), Melanoma and MAPK Pathways (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Sühendan Ekmekçioglu is often cited by papers focused on CAR-T cell therapy research (10 papers), Melanoma and MAPK Pathways (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Sühendan Ekmekçioglu collaborates with scholars based in United States, Australia and Japan. Sühendan Ekmekçioglu's co-authors include Elizabeth A. Grimm, Julie A. Ellerhorst, Sunil Chada, Víctor G. Prieto, Jason Roszik, Abner M. Mhashilkar, Nancy Poı̀ndexter, John B. Mumm, Rajagopal Ramesh and Andrew G. Sikora and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Cancer Research.

In The Last Decade

Sühendan Ekmekçioglu

47 papers receiving 2.4k citations

Peers

Countries citing papers authored by Sühendan Ekmekçioglu

Since Specialization

Citations

This map shows the geographic impact of Sühendan Ekmekçioglu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sühendan Ekmekçioglu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sühendan Ekmekçioglu more than expected).

Fields of papers citing papers by Sühendan Ekmekçioglu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sühendan Ekmekçioglu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sühendan Ekmekçioglu. The network helps show where Sühendan Ekmekçioglu may publish in the future.

Co-authorship network of co-authors of Sühendan Ekmekçioglu

This figure shows the co-authorship network connecting the top 25 collaborators of Sühendan Ekmekçioglu. A scholar is included among the top collaborators of Sühendan Ekmekçioglu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sühendan Ekmekçioglu. Sühendan Ekmekçioglu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Interplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor growth and influences patient survival in melanoma 2022 ·Cell Death and Disease ·Yasunari Fukuda, Matías A. Bustos, (unknown), Jason Roszik, (unknown), (unknown), Jared K. Burks, Jeffrey E. Lee, Elizabeth A. Grimm, Dave S.�B. Hoon, Sühendan Ekmekçioglu	35
2	782 Intratumoral sotigalimab with pembrolizumab activates antigen-presenting cells and induces local and distant anti-tumor responses in first-line metastatic melanoma: results of a phase I/II study 2022 ·Regular and Young Investigator Award Abstracts ·Salah-Eddine Bentebibel, Daniel Johnson, Barbara Pazdrak, Daniel J. McGrail, (unknown), Cara Haymaker, Dzifa Y. Duose, Khalida Wani, Heather M. Sonnemann, Houssein Safa, Jared K. Burks, Patrick Hwu, (unknown), Chantale Bernatchez, Sühendan Ekmekçioglu, Gregory Lizée, Adi Diab	2
3	Molecular Targeting of HuR Oncoprotein Suppresses MITF and Induces Apoptosis in Melanoma Cells 2021 ·Cancers ·Rebaz Ahmed, Ranganayaki Muralidharan, Akhil Srivastava, (unknown), Yan D. Zhao, Sühendan Ekmekçioglu, Anupama Munshi, Rajagopal Ramesh	12
4	169TiP Tocilizumab, ipilimumab, and nivolumab for the treatment of advanced melanoma, non-small cell lung cancer, or urothelial carcinoma 2021 ·Annals of Oncology ·Adi Diab, Noha Abdel‐Wahab, Salah-Eddine Bentebibel, (unknown), (unknown), Sühendan Ekmekçioglu, Jinglin Gao, Mehmet Altan	1
5	Impact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy 2018 ·Frontiers in Oncology ·Sun-Hee Kim, Jason Roszik, Elizabeth A. Grimm, Sühendan Ekmekçioglu	113
6	Cell Surface CD74–MIF Interactions Drive Melanoma Survival in Response to Interferon-γ 2015 ·Journal of Investigative Dermatology ·Keiji Tanese, Yuuri Hashimoto, Zuzana Berkova, Yuling Wang, Felipe Samaniego, Jeffrey E. Lee, Sühendan Ekmekçioglu, Elizabeth A. Grimm	72
7	Inducible Nitric Oxide Synthase Drives mTOR Pathway Activation and Proliferation of Human Melanoma by Reversible Nitrosylation of TSC2 2014 ·Cancer Research ·Esther López-Rivera, Padmini Jayaraman, Falguni Parikh, Michael A. Davies, Sühendan Ekmekçioglu, Sudeh Izadmehr, Denái R. Milton, Jerry E. Chipuk, Elizabeth A. Grimm, Yeriel Estrada, Julio A. Aguirre‐Ghiso, Andrew G. Sikora	80
8	Constitutive Aberrant Endogenous Interleukin-1 Facilitates Inflammation and Growth in Human Melanoma 2011 ·Molecular Cancer Research ·Yong Qin, Sühendan Ekmekçioglu, Ping Liu, Lyn M. Duncan, Gregory Lizée, Nancy Poı̀ndexter, Elizabeth A. Grimm	73
9	The role of melanoma tumor‐derived nitric oxide in the tumor inflammatory microenvironment: Its impact on the chemokine expression profile, including suppression of CXCL10 2011 ·International Journal of Cancer ·Keiji Tanese, Elizabeth A. Grimm, Sühendan Ekmekçioglu	37
10	Targeted Inhibition of Inducible Nitric Oxide Synthase Inhibits Growth of Human Melanoma In vivo and Synergizes with Chemotherapy 2010 ·Clinical Cancer Research ·Andrew G. Sikora, Alexander Gelbard, Michael A. Davies, Daisuke Sano, Sühendan Ekmekçioglu, John Kwon, Yared Hailemichael, Padmini Jayaraman, Jeffrey N. Myers, Elizabeth A. Grimm, Willem W. Overwijk	107
11	Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma 2010 ·Clinical Cancer Research ·Julie A. Ellerhorst, Victoria R. Greene, Sühendan Ekmekçioglu, Carla L. Warneke, Marcella M. Johnson, (unknown), Li‐E Wang, Víctor G. Prieto, Jeffrey E. Gershenwald, Qingyi Wei, Elizabeth A. Grimm	187
12	Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment 2008 ·Melanoma Research ·Cindy S. Hwang, Víctor G. Prieto, A. Hafeez Diwan, Gregory Lizée, Julie A. Ellerhorst, Sühendan Ekmekçioglu, Ping Liu, Omar Eton, (unknown), Elizabeth A. Grimm, Patrick Hwu, Kevin B. Kim	7
13	Phase I trial with a novel orally administered synthetic triterpenoid RTA 402 (CDDO-Me) in patients with solid tumors and lymphoid malignancies 2007 ·Molecular Cancer Therapeutics ·David S. Hong, Razelle Kurzrock, Jeffrey G. Supko, Donald P. Lawrence, Jennifer Wheeler, Joseph P. Eder, (unknown), James W. Mier, Marina Konopleva, Sergej Konoplev, Sühendan Ekmekçioglu, Michael Andreeff, (unknown), Donald Küfe, Colin J. Meyer, Geoffrey I. Shapiro, Bruce J. Dezube	4
14	Soluble Human MDA-7/IL-24: Characterization of the Molecular Form(s) Inhibiting Tumor Growth and Stimulating Monocytes 2006 ·Journal of Interferon & Cytokine Research ·John B. Mumm, Sühendan Ekmekçioglu, Nancy Poı̀ndexter, Sunil Chada, Elizabeth A. Grimm	17
15	Tumor iNOS predicts poor survival for stage III melanoma patients 2006 ·International Journal of Cancer ·Sühendan Ekmekçioglu, Julie A. Ellerhorst, Víctor G. Prieto, Marcella M. Johnson, Lyle D. Broemeling, Elizabeth A. Grimm	113
16	Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10 2006 ·Cancer Immunology Immunotherapy ·Mingzhong Zheng, Dora Bocangel, (unknown), Abner M. Mhashilkar, Rajagopal Ramesh, Kelly K. Hunt, Sühendan Ekmekçioglu, R. Bryan Sutton, Nancy Poı̀ndexter, Elizabeth A. Grimm, Sunil Chada	49
17	Bystander activity of Ad-mda7: Human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism 2004 ·Molecular Therapy ·Sunil Chada, Abner M. Mhashilkar, Rajagopal Ramesh, John B. Mumm, R. Bryan Sutton, Dora Bocangel, Mingzhong Zheng, Elizabeth A. Grimm, Sühendan Ekmekçioglu	89
18	Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression in melanoma cells. 2003 ·PubMed ·Sühendan Ekmekçioglu, Julie A. Ellerhorst, John B. Mumm, Mingzhong Zheng, Lyle D. Broemeling, Víctor G. Prieto, Alexis Stewart, Abner M. Mhashilkar, Sunil Chada, Elizabeth A. Grimm	38
19	The Protein Product of the Tumor Suppressor Gene, Melanoma Differentiation-Associated Gene 7, Exhibits Immunostimulatory Activity and Is Designated IL-24 2002 ·The Journal of Immunology ·Eva G. Caudell, John B. Mumm, Nancy Poı̀ndexter, Sühendan Ekmekçioglu, Abner M. Mhashilkar, Xiaohong Yang, (unknown), (unknown), Sunil Chada, Elizabeth A. Grimm	218
20	Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas 2001 ·International Journal of Cancer ·Sühendan Ekmekçioglu, Julie A. Ellerhorst, Abner M. Mhashilkar, Ayşegül A. Şahin, (unknown), Víctor G. Prieto, Sunil Chada, Elizabeth A. Grimm	92

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact